点击蓝字，关注我们 今日上午港股 1. 中国生物制药(1177.HK) 早盘涨超3%。7月30日，中国生物制药公布，该集团全资附属公司礼新医 药科技(上海)有限公司(礼新医药)与默沙东就LM-299/MK-2010"PD-1/VEGF双抗"的对外授权合作进展 顺利，该集团将于近期收到3亿美元的技术转移里程碑付款。 2. 石药集团(1093.HK) 涨超5%。石药集团宣布，已与Madrigal Pharmaceuticals,Inc.(Madrigal)就集团的 口服小分子激活胰高血糖素样肽-1(GLP-1)受体激动剂SYH2086在全球的开发、生产及商业化订立独 家授权协议。 3. 有赞(8083.HK) 涨超7%。有赞发布公告，预计上半年收益约7.09亿至7.19亿元人民币，同比增加约 3.3%至4.8%；净利润约6800万至7400万元人民币，去年同期为净亏损约人民币429.5万元，同比实现 扭亏为盈，主要得益于整体收入提升；随着AI工具的广泛使用及经营效率提升，人均产出同比提高； 及因历史收购形成的无形资产已于2024年年末完成摊销，相关费用影响消除。 4. 兴证国际(6058.HK) 再涨近18%。据 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy drug, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Group 1: Company Developments - The company reported the death of a third patient treated with ELEVIDYS, resulting in shares closing down $7.89 [1]. - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Group 2: Legal and Regulatory Issues - The lawsuit claims that Sarepta made false statements and failed to disclose critical information, particularly regarding patient safety updates that began on March 18, 2025 [5]. - Following the initial death report, Sarepta halted recruitment and dosing in some clinical studies as requested by EU authorities [6]. - Subsequent deaths of patients treated with ELEVIDYS led to further regulatory scrutiny, including a safety communication from the FDA regarding acute liver failure risks [8]. Group 3: Market Reactions and Analyst Opinions - The financial press reported that following the lawsuit, H.C. Wainwright reduced its price target for Sarepta to $0, reflecting a loss of confidence in the company's future prospects [10]. - The investigation by Hagens Berman is focused on whether Sarepta misled investors about the safety and revenue potential of its gene therapies [11].

周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%， Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美国FDA生物制品评 估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫苗采取严格监管措 施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因疗法和疫苗企业的 利好消息。 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Sarepta Soars After FDA Says Some Patients Can Get Elevidys. Hear about the winners and losers on Wall Street with the Bloomberg Stock Movers report. https://t.co/CnwR9un0jS ...

Shares of Sera Therapeutics up by about 36% in the pre-market. The company says that it will resume shipping Alvdus, that's a muscular disorder gene therapy to patients who can walk. Last week, the FDA recommended a pause in shipments because of serious safety concerns after three deaths of patients who were on this who were on serene therapies. This past weekend, there were reports of a death of another child on Avdus, but the death, the FDA now says, was unrelated to the gene therapy. In a statement, Surr ...

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta ...

In a major win for Sarepta, US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again https://t.co/lnGkzEsubE ...